Hypersensitivity to the active substances or to any of the excipients of the vaccine.
Individuals who develop symptoms indicative of hypersensitivity after receiving a dose of QUADRIVALENT HUMAN PAPILLOMAVIRUS (TYPES 6, 11, 16, 18) RECOMBINANT VACCINE (GARDASIL) should not receive further doses of QUADRIVALENT HUMAN PAPILLOMAVIRUS (TYPES 6, 11, 16, 18) RECOMBINANT VACCINE (GARDASIL).
Other Services
Country
Account